Brief: Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network
14/08/2017 13:30
Aug 14 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O
* Anthera Pharmaceuticals announces result phase 3 clinical
study of Sollpura will be included in the European cystic
fibrosis clinical trial network
* Says topline data are expected at end of 2017 to early
2018, depending on speed of patient enrollment
Source text for Eikon: ID:nGNXODAVTa
Further company coverage: ANTH.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman